Summary: A new study uncovered a novel biological pathway and a promising therapeutic agent capable of slowing the progression of Alzheimer\u2019s disease.The research reveals that the cellular enzyme GRK2 becomes inactivated and aggregates within the brain tissue of dementia patients, damaging mitochondria and triggering a pathological vicious circle of amyloid-beta production.<\/p>\n
To break this destructive feedback loop, a research team developed \u201cCompound 10,\u201d a targeted chemical compound that prevents GRK2 aggregation, preserves mitochondrial energy output, and significantly delays nerve cell death in vivo.<\/p>\n
Key Facts<\/p>\n
The 20-Year Tissue Assay: The foundational research began nearly two decades ago using post-mortem human brain tissue samples removed during tumor surgeries at Ain Shams University Hospital in Cairo, comparing dementia patients against non-dementia controls.The GRK2 Regulatory Engine: Professor Ursula Quitterer focused her research on G protein-coupled receptor kinase 2 (GRK2), a vital regulatory protein that helps cells in the brain and heart respond correctly to cellular stress and environmental strain.The Inactivation and Aggregation Mechanism: Molecular analyses of human tissues and mouse models unmasked a specific pathological shift in Alzheimer\u2019s brains, where metabolic changes convert functional GRK2 into an inactive form that clumps together into harmful aggregates.Mitochondrial Pore Blockade: These inactive GRK2 aggregates deposit directly onto mitochondria (the cellular powerhouses), blocking their pores, starving the nerve cells of energy, and inducing severe intracellular stress.The Amyloid-Beta Vicious Circle: The researchers demonstrated that inactive GRK2 directly accelerates the production of toxic amyloid-beta fragments. In turn, the amyloid-beta inflicts further stress on nerve cells, forcing more functional GRK2 to inactivate and aggregate in a self-perpetuating cycle.Compound 10 Efficacy: To disrupt this loop, the ETH Zurich team synthesized and screened multiple chemical agents, identifying \u201cCompound 10\u201d as a highly effective inhibitor of GRK2 aggregation. In mouse models, the substance optimized mitochondrial function, lowered amyloid-beta accumulation, and prolonged animal survival.Systemic Anti-Aging Side Benefits: Beyond shielding cerebral infrastructure, mice treated with Compound 10 exhibited improved cardiac function and systemic anti-aging markers, such as developing significantly fewer gray hairs in old age.The Extended Longitudinal Timeline: Because Alzheimer\u2019s is an age-related condition, basic validation required working with older mice aged 1.5 to 2 years, meaning each sequential, interlocking experiment took up to two years to complete. The basic research is now finalized, and a patent has been filed.<\/p>\n
Source: ETH Zurich<\/p>\n
\u201cCompound 10\u201d is how Ursula Quitterer refers to the chemical compound that her team has developed and which could slow down the progression of Alzheimer\u2019s disease. <\/p>\n
Quitterer is Professor of Molecular Pharmacology at ETH Zurich and has so far tested the active ingredient first on mice, revealing promising effects: the typical death of nerve cells seen in dementia is significantly slower, and the animals survive for longer.<\/p>\n
The new substance is the result of research that began almost 20 years ago, when Quitterer received tissue samples from patients of a doctor and colleague at the Ain Shams University Hospital in Cairo. These were samples of brain tissue that the doctor had removed during tumour surgery \u2013 both on people diagnosed with dementia and non-dementia patients.\u00a0<\/p>\n
New point of attack for drug<\/p>\n
Quitterer set about working on these samples \u2013 but to understand what exactly she did with them, we first need a bit of background. Then, as now, the main focus of her research was a bodily enzyme that performs a vital role in many human cells: GRK2. As a regulatory protein, this enzyme helps cells respond correctly to signals, stress and strain. As well as in the heart, for example, it is also active in the brain \u2013 where it supports the function of nerve cells.<\/p>\n
Through molecular analyses of the tissue samples from Cairo and research on mice, Quitterer\u2019s team showed what an important role the enzyme GRK2 plays in dementia.<\/p>\n
The researchers recently published their findings in the journal\u00a0Cell Reports Medicine.<\/p>\n
When the protective protein stops working<\/p>\n
Two forms of the enzyme GRK2 occur in cells: a normal, functional form and a form that has been inactivated by the cellular metabolism. Quitterer and her team discovered that the inactivated form occurs in large quantities in the brain tissue of dementia patients. They were able to demonstrate the same thing in mice \u2013 specifically in a mouse model for Alzheimer\u2019s disease.<\/p>\n
The researchers also showed that the inactive form of this enzyme forms aggregates in brain cells in the event of dementia. These aggregates deposit on \u2013 and damage \u2013 the mitochondria (the \u201cpowerhouses\u201d of the cells). \u201cThe GRK2 aggregates block the pores of the mitochondria, reducing the amount of energy they can supply and leading to a situation of stress inside the cells,\u201d Quitterer explains.<\/p>\n
In experiments on mice, the researchers also observed that the inactive GRK2 promotes the production of amyloid beta, a protein fragment that is considered a main cause of Alzheimer\u2019s.<\/p>\n
What\u2019s more, this leads to a self-perpetuating process: amyloid beta puts stress on the nerve cells and, in turn, this stress leads to the formation of more inactive and aggregated GRK2 \u2013 creating a vicious circle that contributes to the progression of dementia.<\/p>\n
Anti-ageing effect<\/p>\n
With a view to breaking this vicious circle, Quitterer and her colleagues developed several chemical compounds, which they tested in cell culture experiments and on mice. Here, compound 10 proved to be particularly effective, preventing the GRK2 molecules from forming aggregates. As a result, the mitochondria work better, there is less deposition of amyloid beta in the cells, and the nerve cells maintain their function and do not die off.<\/p>\n
In the mice, the team also observed effects outside the brain. Compound 10 had a positive influence on heart function and ageing processes. For example, the animals developed fewer grey hairs in old age.<\/p>\n
Why the research took so long<\/p>\n
The researchers have applied for a patent on compound 10, and the basic research is now complete. \u201cIt took so long simply because everything takes so long in Alzheimer\u2019s research,\u201d explains Quitterer. As the researchers were investigating an age-related disease, they worked with older animals. For mice, this means an age of one and a half to two years. And it takes about one and a half to two years to complete each experiment from which conclusions can be drawn that then lead to the planning of the next experiment. \u201cIt\u2019s all a great deal slower than in cancer research, for example.\u201d<\/p>\n
Now, Quitterer and ETH Zurich are looking for a company that is interested in taking the next steps towards developing a drug.<\/p>\n
\u201cAlzheimer\u2019s is a very complex disease,\u201d says Quitterer. Current medications do not cure the disease, but rather \u2013 at most \u2013 delay its progression by several months. \u201cThat\u2019s why it\u2019s so important that we\u2019ve now identified a new target protein in the form of GRK2, as well as an active ingredient that operates via GRK2 and therefore via a different mechanism than existing Alzheimer\u2019s drugs.\u201d Using compound 10 in combination with other medications, it may one day be possible to improve quality of life for patients.<\/p>\n
Key Questions Answered:Q: How can a single enzyme meant to protect brain cells end up causing them to starve and die?<\/p>\n
A: Through a metabolic malfunction. When a person develops dementia, the vital regulatory enzyme GRK2 becomes inactivated and clumps into large aggregates. These sticky clusters blanket the mitochondria, blocking their pores and stripping the nerve cells of the energy they need to survive.<\/p>\n
Q: What makes the \u201cvicious circle\u201d of Alzheimer\u2019s progression so difficult to interrupt with traditional medicine?<\/p>\n
A: Its self-perpetuating nature. The inactive, aggregated GRK2 enzymes force the brain to produce more toxic amyloid-beta. This amyloid-beta accumulation places immense stress on surrounding nerve cells, which in turn causes even more functional GRK2 to shut down and aggregate, locking the disease in a destructive loop.<\/p>\n
Q: Why did it take nearly 20 years for ETH Zurich to complete the foundational research for Compound 10?<\/p>\n
A: Because testing age-related diseases operates on a fixed biological clock. To replicate human dementia accurately, researchers must use older mice that are one and a half to two years old. Because each individual experiment takes up to two years to unfold before data can be extracted, the research pipeline moves much slower than in other medical fields.<\/p>\n
Editorial Notes:This article was edited by a Neuroscience News editor.Journal paper reviewed in full.Additional context added by our staff.About this Alzheimer\u2019s disease and neuropharmacology research news<\/p>\n
Author:\u00a0Marianne Lucien<\/a>
Source:\u00a0ETH Zurich<\/a>
Contact:\u00a0Marianne Lucien \u2013 ETH Zurich
Image:\u00a0The image is credited to Neuroscience News<\/p>\n